Pioglitazone randomised Italian study on metabolic syndrome (PRISMA): Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients

S. Genovese, A. Passaro, P. Brunetti, M. Comaschi, D. Cucinotta, C. G. Egan, B. Chinea, F. Bravi, C. Di Pietro

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p

Original languageEnglish
Pages (from-to)606-616
Number of pages11
JournalJournal of Endocrinological Investigation
Volume36
Issue number8
DOIs
Publication statusPublished - Sep 2013

Keywords

  • HDL-cholesterol
  • Metabolic syndrome
  • Pioglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Pioglitazone randomised Italian study on metabolic syndrome (PRISMA): Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients'. Together they form a unique fingerprint.

Cite this